Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.44 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13009187 | 0.91 | SMN1; SMN2 (0.55) | LTA4HSMN1; SMN2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL13474891 | 0.89 | MAPT (0.57) | SMN1; SMN2CYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL18118971 | 0.88 | CYP3A4 (0.59) | SMN1; SMN2CYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL5671239 | 0.86 | CYP2C9 (0.54) | LTA4HSMN1; SMN2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL146154 | 0.86 | ACHE (0.52) | SMN1; SMN2CYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL15576545 | 0.86 | CYP3A4 (0.57) | SMN1; SMN2CYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL13790956 | 0.85 | SMN1; SMN2 (0.62) | LTA4HSMN1; SMN2ALDH1A1HTTMAPT | |
| SCHEMBL12293087 | 0.85 | HTT (0.50) | SMN1; SMN2CYP3A4CYP2C9CYP2C19ALDH1A1 | |
| Hydrochloric Acid SCHEMBL29893927 | 0.84 | ACHE (0.50) | SMN1; SMN2CYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL1284070 | 0.84 | ALDH1A1 (0.67) | SMN1; SMN2CYP3A4CYP2C9CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716491-B2 | Benzimidazolium dyes and their use as fluorescent chemosensors | NEW YORK UNIVERSITY (US) | 2014-05-06 | — | — | US | disclosed |
| US-8133898-B2 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-13 | — | — | US | disclosed |
| US-8133898-B2 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20110301192-A1 | Inhibitors of Cyclin Kinase Inhibitor p21 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110224231-A1 | Novel Lactams as Beta Secretase Inhibitors | PFIZER INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-7947712-B2 | Antiarthritic agents; asthma; chronic obstructive pulminary diosrders; atherosclerosis; vision defects; hepatitis; central nervous system disorders; cardiovascular disorders; wound healing agents; restenosis; cirrhosis; multiple sclerosis; glomerulonephritis; graft versus host disease; antidiabetic agent | WYETH LLC (US) | 2011-05-24 | — | — | US | disclosed |
| US-20100137310-A1 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-03 | — | — | US | disclosed |
| US-20080269213-A1 | 8-Hydroxyquinoline compounds and methods thereof | WYETH (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080160521-A1 | BENZIMIDAZOLIUM DYES AND THEIR USE AS FLUORESCENT CHEMOSENSORS | NEW YORK UNIVERSITY (US) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137310-A1 | RENIN INHIBITORS | REN, ACE, PRSS3 | LTA4H 752/4885SMN1; SMN2 4780/4885CYP3A4 49/4885 |
| US-20080269213-A1 | 8-Hydroxyquinoline compounds and methods thereof | MMP8, MMP26, MMP9 | LTA4H 288/4885SMN1; SMN2 598/4885CYP3A4 1436/4885 |
| US-20080160521-A1 | BENZIMIDAZOLIUM DYES AND THEIR USE AS FLUORESCENT CHEMOSENSORS | IK, C9, CBR3 | LTA4H 521/4885SMN1; SMN2 3488/4885CYP3A4 840/4885 |
| US-20110301192-A1 | Inhibitors of Cyclin Kinase Inhibitor p21 | CDKN1A, CCNI, CDK2 | LTA4H 3233/4885SMN1; SMN2 4021/4885CYP3A4 3206/4885 |
| US-20110224231-A1 | Novel Lactams as Beta Secretase Inhibitors | BACE1, BACE2, APH1B | LTA4H 657/4885SMN1; SMN2 361/4885CYP3A4 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.